Status:
COMPLETED
Anti-ficolin-3 Antibodies in Lupus Nephritis
Lead Sponsor:
University Hospital, Grenoble
Collaborating Sponsors:
Institut de Biologie Structurale Grenoble
Conditions:
Systemic Lupus Erythematosus Nephritis
Eligibility:
All Genders
18+ years
Brief Summary
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of multiple autoantibodies and accumulation of immune complexes resulting in systemic inflammatory re...
Detailed Description
PRIMARY OUTCOME MEASURE Exploration of the inhibition of anti-ficolin-3 antibodies purified from the serum of 14 patients with active lupus nephritis in ficolin-3-dependent necrotic cells recognition....
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Age ≥ 18 years old
- Patients who have valid health insurance
- Non-opposition to participation obtained
- Diagnostic de lupus according to SLICC 2012, performed more than 3 months ago.
- Active lupus nephritis defined by :
- elevated SLEDAI indexes (≥ 4), the presence of a significant proteinuria (≥ 0.5 g/day) and/or the presence of hematuria, aseptic leukocyturia or urinary casts, and documented by renal biopsy and classified according to the ISN/RPS classification.
- Non-inclusion Criteria:
- Patient with a known progressing cancer
- Patient who had started lupus nephritis flare treatment
- Participant involved in another interventional clinical study
- Person deprived of liberty by judicial order
- Person under guardianship or curatorship
- Hemoglobin level \< 7 g/dL
Exclusion
Key Trial Info
Start Date :
March 7 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 20 2020
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT03842787
Start Date
March 7 2019
End Date
June 20 2020
Last Update
September 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
JOUVE
La Tronche, France